Sun Pharma to acquire Organon for $11.75bn

Sun Pharmaceutical Industries has signed a definitive statement to get Organon successful a transaction with an endeavor valuation of $11.75bn successful cash, paying $14.00 per stock for each outstanding shares.

Organon, created done a spinoff from Merck & Co (MSD) successful 2021, distributes much than 70 products crossed women’s wellness and wide medicines, including biosimilars, reaching 140 countries.

The company’s cardinal markets see Brazil, Canada, China, the European Union (EU), and the US. Its manufacturing web comprises six facilities successful emerging markets and the EU.

Following completion of the transaction, Sun Pharma volition person a combined gross of $12.4bn.

The institution volition run crossed 150 countries, with 18 markets exceeding $100m successful revenues each.

The woody is projected to astir treble its net earlier interest, taxes, depreciation and amortisation (EBITDA) and currency flow, resulting successful post-transaction nett debt/EBITDA of 2.3×.

Organon’s portfolio and stakeholder relationships are expected to complement Sun Pharma’s business.

The boards of some companies person approved the transaction. The statement remains taxable to regulatory and Organon stockholder approvals, with closing projected for aboriginal 2027.

Sun Pharma enforcement president Dilip Shanghvi said: “This transaction represents a important accidental for Sun Pharma to physique connected its imaginativeness of Reaching People and Touching Lives.

“Organon’s portfolio, capabilities and planetary scope are highly complementary to our own, and we judge that bringing the 2 organisations unneurotic tin make a stronger and much diversified platform.

“We person heavy respect for Organon’s ngo and look guardant to gathering connected its bequest portion driving sustainable long‑term growth.”

Organon reported gross of $6.2bn and adjusted EBITDA of $1.9bn for the twelvemonth ending December 2025.

The institution precocious completed a merchandise divestiture with $440m successful upfront payment, enhancing its March 2026 currency balance.

In March 2025, Sun Pharma agreed to get Checkpoint Therapeutics, a specializer successful immunotherapy and targeted oncology treatments, for an aggregate upfront terms of $355m.

"Sun Pharma to get Organon for $11.75bn" was primitively created and published by Pharmaceutical Technology, a GlobalData owned brand.

The accusation connected this tract has been included successful bully religion for wide informational purposes only. It is not intended to magnitude to proposal connected which you should rely, and we springiness nary representation, warranty oregon guarantee, whether explicit oregon implied arsenic to its accuracy oregon completeness. You indispensable get nonrecreational oregon specializer proposal earlier taking, oregon refraining from, immoderate enactment connected the ground of the contented connected our site.